Bayer Updates Progress In Transforming Pharma Business Through Innovation In Healthcare
LEVERKUSEN (dpa-AFX) - Bayer AG Wednesday updated its progress in transforming its pharmaceutical business with breakthrough innovation in healthcare.
At its virtual Pharma Media Day, under the theme Transforming Healthcare. Transforming Bayer , the company revealed innovation in cell and gene therapy as well as digital health that will significantly help patients suffering from conditions that are currently still difficult to treat.
Bayer said it recently heavily invested in external innovation with more than 25 collaboration agreements and acquisitions.
Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer s Pharmaceuticals Division, said, We are driving this transformation and growing our promising development portfolio together with our partners. Our joint goal is to bring breakthrough treatments to patients and make healthcare systems more sustainable in the
Cell and gene therapies can radically change treatment
13 Jan 2021
Mariecar Jara-Puyod,
Senior Reporter
Cell and gene therapies combined with the burgeoning digital health and artificial intelligence shall remain to be a nucleus and continually pivot the intensely-competitive pharmaceutical industry, accelerating solutions for improved health and better outcomes.
This was emphasised at the “Virtual Pharma Media Day” of the healthcare-agriculture global enterprise Bayer on Wednesday (noon to 2.30 pm, UAE time), attended by 200 journalists from 30 countries. Cell therapy is the delivery or injection of “functioning cells into a patient’s body to achieve a medicinal effect-to prevent, manage or cure a certain illness or to repair and regenerate damaged cells.”
Bayer to support development and supply of CVnCoV COVID-19 vaccine
SHARES
Bayer has signed a collaboration and services agreement with CureVac for the development of CVnCoV, a COVID-19 vaccine currently in late-stage trials.
Bayer has agreed to support the further development, supply and key territory operations of the CVnCoV COVID-19 vaccine candidate by signing a collaboration and services agreement with CureVac.
According to the enterprises, Bayer will facilitate this by contributing its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance and support in selected countries.
“The need for vaccines against COVID-19 is enormous. We are therefore pleased to be able to provide significant support to CureVac, a leader in mRNA technology, in advancing the further development and supply of its COVID-19 vaccine candidate,” said Stefan Oelrich, Member of the Board of Manag
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
Companies enter into a collaboration and services agreement / Bayer to support CureVac in numerous areas, including development and supply of CVnCoV / CureVac benefits from Bayer´s expertise and established infrastructure / Plan to facilitate the supply of several hundred million doses
Berlin and Tübingen, Germany / Boston, USA, January 7, 2021 – Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain
CureVac and Bayer team up to advance COVID-19 vaccine candidate Pharmaceutical giant Bayer will support development of CureVac’s mRNA COVID-19 vaccine candidate across numerous areas: helping facilitate the global supply of several hundred million doses.
CureVac – whose vaccine candidate CVnCoV headed into Phase 3 trials in December – will benefit from Bayer’s expertise and established infrastructure as it takes the vaccine forward through clinical trials, authorization and mass production and supply.
The collaboration and services agreement will see Bayer support fellow German company and mRNA specialist CureVac in further development, supply and key territory operations of the vaccine candidate. This includes areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information and supply chain performance.